Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54.
暂无分享,去创建一个
Marc P. Bonaca | Deepak L. Bhatt | A. Parkhomenko | M. Sabatine | E. Braunwald | S. Murphy | G. Montalescot | P. Steg | P. Théroux | G. Magnani | R. Storey | P. Johanson | Marc Cohen | G. Kamenský | A. Goudev | K. Im | T. O. Ophuis | E. Jensen | D. Isaza | P. Théroux | Mikhail Rudah
[1] Marc P. Bonaca,et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. , 2016, European heart journal.
[2] T. Jernberg,et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. , 2015, European heart journal.
[3] Marc P. Bonaca,et al. Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.
[4] A. Jaffe,et al. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .
[5] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[6] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[7] Marc P. Bonaca,et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. , 2014, American heart journal.
[8] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[9] Deepak L. Bhatt,et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.
[10] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[11] Deepak L. Bhatt,et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.
[12] Patrice Cacoub,et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.
[13] A. Connor,et al. The way I see it: House officers need formal career development , 2002 .
[14] A. Mattioli,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[15] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[16] L Ryan,et al. Survival analysis in natural history studies of disease. , 1989, Statistics in medicine.
[17] Nicholas P. Jewell,et al. A note on the product-limit estimator under right censoring and left truncation , 1987 .